Relyto 100 IV100mg/10ml

Rituximab is used in the treatment of non-Hodgkin lymphoma (NHL), rheumatoid arthritis, blood cancer (chronic lymphocytic leukemia), granulomatosis with polyangiitis and microscopic polyangiitis. Rituximab is given as an injection under the supervision of doctor. You must take it in a dose as advised by the doctor. Your doctor will decide what dose is necessary and how often you need to take it. This will depend on what you are being treated for and may change from time to time. You should take it exactly as your doctor has advised. Taking it in the wrong way or taking too much can cause very serious side effects. It may take several weeks or months for you to see or feel the benefits but do not stop taking it unless your doctor tells you to. The most common side effects of this medicine include headache, weakness, edema, infection, and hair loss. This medicine may reduce the number of blood cells (decrease red blood and white blood cells) in your blood, thereby, increasing the susceptibility to infections. Regular blood tests are required to check your blood cells along with hepatitis B. Before taking it, tell your doctor if you have heart disease, liver, or planning surgery or vaccination or are taking any medicines to treat infections. Many other medicines can affect, or be affected by, this medicine so let your doctor know all medications you are using. This medicine is not recommended during pregnancy or while breastfeeding. The use of effective contraception by both males and females during treatment is important to avoid pregnancy. Rituximab is a monoclonal antibody. It works by targeting the unwanted activity of immune cells (B cells) in rheumatoid arthritis and certain types of cancers.

• Non-Hodgkin lymphoma (NHL) • Rheumatoid arthritis • Blood cancer (Chronic lymphocytic leukemia) • Granulomatosis with polyangiitis • Microscopic polyangiitis

Rituximab is a chimeric monoclonal antibody to CD20 antigen which regulates cell cycle initiation. It binds to the antigen on the cell surface, activating complement-dependent B-cell cytotoxicity; and to human Fc receptors, mediating cell killing through an antibody-dependent cellular toxicity.

Adult Dose: Intravenous Non-Hodgkin Lymphoma Recommended dose for NHL 375 mg/m² IV infusion according to the following schedules Relapsed or refractory low-grade or follicular, CD20-positive, B-cell NHL: Once weekly x4-8 doses Retreatment for relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL: Once weekly x4 doses Previously untreated, follicular, CD20-positive, B-cell NHL: Administer on Day 1 of each chemotherapy cycle for up to 8 doses; with complete or partial response, initiate maintenance 8 weeks following completion of combination chemotherapy as a single-agent q8weeks for 12 doses Nonprogressing, low-grade, CD20-positive, B-cell NHL, after first-line CVP chemotherapy: Following completion of 6-8 cycles of CVP chemotherapy, administer once weekly for 4 doses at 6-month intervals to a maximum of 16 doses Diffuse large B-cell NHL: Administer on Day 1 of each cycle of chemotherapy for up to 8 infusions Chronic Lymphocytic Leukemia Indicated for untreated and previously treated CD20-positive CLL; combined therapy with fludarabine and cyclophosphamide (FC) 375 mg/m² IV infusion on day 1 of 1st cycle (for 1st cycle, administer 1 day before chemotherapy with FC), THEN 500 mg/m² IV on day 1 of subsequent cycles (administer on same day as chemotherapy with FC) Repeat q28 days x6 cycles Fludarabine & cyclophosphamide dosage Fludarabine: 25 mg/m² IV qDay x 3 days Cyclophosphamide: 250 mg/m² IV qDay x3 days Repeat q28 days x 6 cycles Rheumatoid Arthritis 1000 mg IV infusion, repeat after 2 week (2 infusions separated by 2 week is 1 course) Repeat course q24weeks or based on clinical evaluation (but no sooner than 16 weeks) Used in combo with methotrexate Premedicate with glucocorticoids 30 minutes before infusion to reduce infusion rxn Not to exceed 1000 mg/dose Child Dose: Safety and efficacy not established

Your doctor or nurse will give you this medicine. Kindly do not self administer.

If you miss a dose of Rituximab, please consult your doctor.

Common: • Headache • Weakness • Edema (swelling) • Infection • Hair loss • Itching • Chills • Febrile neutropenia • Decreased white blood cell count (neutrophils) • Infusion reaction • Increased risk of infection • Decreased blood cells (red cells, white cells, and platelets)

[CONSULT YOUR DOCTOR] It is not known whether Rituximab alters the ability to drive. Do not drive if you experience any symptoms that affect your ability to concentrate and react. It is given as a drip (intravenous infusion) by your doctor or nurse. You may be given some painkillers, antihistamine and possibly steroids before the drip to help prevent infusion reaction. Your doctor may get blood tests done to check for hepatitis B before treatment and to monitor your blood cells during treatment with this medicine. Inform your doctor immediately if you notice any signs of infection such as fever, sore throat or rash. Inform your doctor if you are pregnant, planning to conceive or breastfeeding. Inform your doctor if you have any heart rhythm problems, if you are having surgery or if you plan to get any vaccinations.

Lactation. Type I hypersensitivity or anaphylactic reactions to murine proteins or component of the formulation.

Increased risk of renal toxicity w/ cisplatin. Potentially Fatal: May decrease the efficacy of vaccines and increase the risk of infections in patients immunised w/ live vaccines.

[CAUTION] Caution is advised when consuming alcohol with Rituximab. Please consult your doctor.

[CONSULT YOUR DOCTOR] Rituximab may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.

[SAFE IF PRESCRIBED] Rituximab is probably safe to use during breastfeeding. Limited human data suggests that the drug does not represent any significant risk to the baby.

[SAFE IF PRESCRIBED] Rituximab is probably safe to use in patients with kidney disease. Limited data available suggests that dose adjustment of Rituximab may not be needed in these patients. Please consult your doctor. [CONSULT YOUR DOCTOR] There is limited information available on the use of Rituximab in patients with liver disease. Please consult your doctor. Use of Rituximab is not recommended in patients with the active liver disease or those who had viral hepatitis as it can reactivate the infection.

Non Hodgkin lymphoma of defuss large b cells I am very much experienced in treating DLBCL Symptoms of lymphoma And blood cancer Symptoms could be like fever, weight loss, anorexia, lymphadenopathy. Rheumatoid arthritis patient ok Dear mam as your case is a chronic case it requires long case taking, examination and regular follow up, therefore, please visit a homeopath so that he can examine you and guide you accordingly. I have non hodgking's lymphoma. What type of treament i need? And it this cancer curable? If CD 20+ TAKE R-CHOP TREATMENT Rheumatoid arthritis with osteoarthritis Please refer to a Rheumatologist I have joint pain in my rt wrist since 6 yrs. What are the possible reasons? It may be Tenosynovitis, or Rheumatoid arthritis or any other type of arthritis Sir/Ma'am, I feel pain in the heel of both the legs especially when I get up from the bed in the morning. After walking couple of steps, it goes away. there is no bone problem reported in the Xray report. Please guide me what could be the reason? This is the test for rheumatoid arthritis What is gatheya. What is it solution It is supposed to be Rheumatoid Arthritis